|
gptkbp:instanceOf
|
gptkb:chemical_compound
Hallucinogen
|
|
gptkbp:actsOn
|
serotonin receptors
|
|
gptkbp:appearance
|
white crystalline solid
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:biosynthesized_from
|
animals
humans
plants
|
|
gptkbp:boilingPoint
|
160 °C (at 0.2 mmHg)
|
|
gptkbp:CASNumber
|
61-50-7
|
|
gptkbp:category
|
alkaloid
Hallucinogen
psychedelic tryptamine
|
|
gptkbp:chemicalFormula
|
C12H16N2
|
|
gptkbp:discoveredBy
|
gptkb:Richard_Helmuth_Fredrick_Manske
|
|
gptkbp:discoveredIn
|
1931
|
|
gptkbp:durationOfEffects
|
2–6 hours (oral, with MAOI)
5–30 minutes (inhaled)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:foundIn
|
gptkb:Ayahuasca
certain plants
|
|
gptkbp:hasInChIKey
|
gptkb:RBJJMJOCELJQQY-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
CN(C)CCc1c[nH]c2cccc(C1)2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DMT
|
|
gptkbp:IUPACName
|
2-(1H-indol-3-yl)-N,N-dimethylethanamine
|
|
gptkbp:legalStatus
|
gptkb:Schedule_III_(Canada)
gptkb:Schedule_I_(US)
gptkb:Class_A_(UK)
Schedule 9 (Australia)
|
|
gptkbp:meltingPoint
|
44.6 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
188.27 g/mol
|
|
gptkbp:otherName
|
gptkb:N,N-Dimethyltryptamine
|
|
gptkbp:PubChem_CID
|
gptkb:CHEBI:4611
gptkb:CHEMBL39122
gptkb:DB01486
6089
|
|
gptkbp:relatedTo
|
gptkb:5-MeO-DMT
gptkb:bufotenin
psilocybin
serotonin
|
|
gptkbp:routeOfAdministration
|
injection
oral
inhalation
|
|
gptkbp:sideEffect
|
nausea
anxiety
increased heart rate
euphoria
hallucinations
|
|
gptkbp:solubility
|
slightly soluble
|
|
gptkbp:UNII
|
WUB6018W98
|
|
gptkbp:usedFor
|
recreational purposes
shamanic rituals
|
|
gptkbp:bfsParent
|
gptkb:Ayahuasca
gptkb:ayahuasca
gptkb:psilocin
gptkb:psychedelic_movement
gptkb:Hallucinogen
gptkb:lysergic_acid_diethylamide
gptkb:Phalaris
gptkb:bufotenin
|
|
gptkbp:bfsLayer
|
6
|